<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804449</url>
  </required_header>
  <id_info>
    <org_study_id>15303</org_study_id>
    <nct_id>NCT04804449</nct_id>
  </id_info>
  <brief_title>Prospective Longitudinal Effects of Intra-articular Corticosteroid Injection on Synovial Fluid Oxygen</brief_title>
  <acronym>POLO</acronym>
  <official_title>Prospective Longitudinal Effects of Intra-articular Corticosteroid Injection on Synovial Fluid Oxygen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory arthritis such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are&#xD;
      characterized by synovial inflammation of joints, potentially leading to joint destruction&#xD;
      and functional disability. Inflamed joints have lower oxygen levels. Studying how oxygen&#xD;
      level within the joint affect inflammation may lead to new treatments for patients with&#xD;
      arthritis. Anti-inflammatory corticosteroid injection into the joint is well tolerated and&#xD;
      widely used in clinical practice but its effects on oxygen level within joints is unknown.&#xD;
      Therefore, patients who require corticosteroid injection into the joint as routine clinical&#xD;
      care will have biological samples collected before and after the injection. This will give&#xD;
      new information to put into context the biological effects within the joint, and accelerate&#xD;
      development of new treatment approaches in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of intra-articular corticosteroid injection on joint oxygen tension in patients with rheumatoid and psoriatic arthritis</measure>
    <time_frame>Day 28</time_frame>
    <description>Change from Baseline Synovial fluid partial pressure of oxygen at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of intra-articular corticosteroid injection on joint hypoxia in patients with rheumatoid and psoriatic arthritis</measure>
    <time_frame>Day 1 and 28</time_frame>
    <description>Hypoxia-inducible factor 1α (HIF-1α) protein levels in synovial tissues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of intra-articular corticosteroid injection on synovial fibroblast protein expression</measure>
    <time_frame>Day 28</time_frame>
    <description>Change from baseline protein expression levels in synovial fibroblasts at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of intra-articular corticosteroid injection on patient satisfaction</measure>
    <time_frame>Day 28</time_frame>
    <description>Treatment Satisfaction Questionnaire (TSQM)©</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis and psoriatic arthritis</arm_group_label>
    <description>Patients with rheumatoid arthritis or psoriatic arthritis, who require an intra-articular corticosteroid injection</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants with rheumatoid arthritis or psoriatic arthritis who require&#xD;
        intra-articular corticosteroid injection, and swollen joint suitable for ultrasound guided&#xD;
        synovial biopsy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is willing and able to give informed consent for participation in the&#xD;
             study.&#xD;
&#xD;
          -  Male or Female, aged 18 years or above.&#xD;
&#xD;
          -  Fulfil American College of Rheumatology/European League Against Rheumatism criteria&#xD;
             (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria or fulfil Classification&#xD;
             Criteria for Psoriatic Arthritis 2006 (CASPAR).&#xD;
&#xD;
          -  Participant has been selected for intra-articular corticosteroid injection as part of&#xD;
             their routine clinical care.&#xD;
&#xD;
          -  Selected joint for biopsy must be minimum Grade 2 synovial thickening for large joint&#xD;
             (knee) and medium joint (wrist), or minimum Grade 3 synovial thickening for small&#xD;
             joint (metacarpophalangeal).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current enrolment in any other clinical study involving an investigational study&#xD;
             treatment.&#xD;
&#xD;
          -  Intramuscular, intravenous or intra-articular administration of corticosteroid within&#xD;
             4 weeks prior to baseline visit.&#xD;
&#xD;
          -  Oral corticosteroid &gt; 10 mg/day prednisolone or equivalent within 4 weeks prior to&#xD;
             baseline visit.&#xD;
&#xD;
          -  Oral corticosteroid dose not stable for at least 4 weeks prior to baseline visit.&#xD;
&#xD;
          -  Oral non-steroidal anti-inflammatory drugs (including aspirin &gt; 75 mg/ day and&#xD;
             selective-cyclooxygenase inhibitors) dose not stable for at least 4 weeks prior to&#xD;
             baseline visit.&#xD;
&#xD;
          -  Disease modifying anti-rheumatic drugs (DMARDs) dose not stable for at least 4 weeks&#xD;
             prior to baseline visit.&#xD;
&#xD;
          -  History of septic arthritis.&#xD;
&#xD;
          -  Participants on warfarin, heparin, low molecular weight heparin, direct oral&#xD;
             anticoagulants. Oral anti-platelet agents are permitted.&#xD;
&#xD;
          -  History of haemophilia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shing Law, BM BCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shing Law, BM BCh</last_name>
    <phone>+44(0)1865737882</phone>
    <email>shing.law@ndorms.ox.ac.uk</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

